The US Food and Drug Administration (FDA) has cleared pharmaceutical company Glenmark’s investigational new drug (IND) application to begin a phase I trial of GBR 1302-BEAT to treat HER2+ cancers.
Bi-specific engagement by antibodies based on the T-cell receptor (BEAT) has been designed to produce bi-specific antibodies (bsAbs) that engage with two targets to affect cancer cells, which in the case of HER2+ cancers redirects cytolitic T-cells.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Glenmark president and chief medical officer Fred Grossman said: “We believe GBR 1302 may have utility across a broad range of HER2+ tumour types.
“Data from preclinical studies are very encouraging.
“Based on its novel mechanism of redirecting T-cells to HER2+ cancer cells, GBR 1302 has the potential to become an important therapy for previously treated and, eventually, newly diagnosed HER2+ tumours.”
The phase I trial will be carried out in two parts, the dose escalation and expansion.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe dose-escalation will examine patients with previously treated HER2+ tumours in order to test safety and tolerability, as well as the pharmacokinetics and preliminary anti-tumour activity of the maximum dose of GBR 1302-BEAT .
The expansion will examine the same population treated with the maximum tolerated dose to determine early proof-of-concept.
Preclinical studies suggested that GBR 1302 is supposedly active against a range of HER2-expressing tumour types, including breast, gastric and other cancers.
